# | Title | Journal | Year | Citations |
---|
1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | New England Journal of Medicine | 2015 | 6,773 |
2 | Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Lancet, The | 2016 | 5,456 |
3 | Guidelines for the use and interpretation of assays for monitoring autophagy | Autophagy | 2012 | 3,122 |
4 | The biology and management of non-small cell lung cancer | Nature | 2018 | 2,877 |
5 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
6 | How We Design Feasibility Studies | American Journal of Preventive Medicine | 2009 | 2,233 |
7 | MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Nature | 2014 | 2,109 |
8 | American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer | Journal of Clinical Oncology | 2007 | 1,998 |
9 | Longitudinal analyses reveal immunological misfiring in severe COVID-19 | Nature | 2020 | 1,710 |
10 | Pembrolizumab for Early Triple-Negative Breast Cancer | New England Journal of Medicine | 2020 | 1,542 |
11 | Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study | Journal of Clinical Oncology | 2011 | 1,501 |
12 | A History of Cancer Chemotherapy | Cancer Research | 2008 | 1,362 |
13 | Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer | JAMA Oncology | 2018 | 1,350 |
14 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Lancet Oncology, The | 2012 | 995 |
15 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | Lancet, The | 2018 | 984 |
16 | Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer | Science | 2017 | 983 |
17 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 943 |
18 | Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study | Journal of Clinical Oncology | 2012 | 931 |
19 | Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study | Journal of Clinical Oncology | 2016 | 868 |
20 | Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study | Lancet Haematology,the | 2020 | 848 |
21 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2020 | 848 |
22 | Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 762 |
23 | Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 760 |
24 | FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis | Lancet Oncology, The | 2016 | 719 |
25 | Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities | Cancer Discovery | 2015 | 696 |
26 | Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | New England Journal of Medicine | 2018 | 691 |
27 | Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update | Journal of Clinical Oncology | 2020 | 673 |
28 | Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 672 |
29 | ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer | Journal of Clinical Oncology | 2019 | 643 |
30 | Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer | JAMA Oncology | 2020 | 611 |
31 | Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial | Lancet Oncology, The | 2016 | 594 |
32 | Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial | Annals of Oncology | 2013 | 567 |
33 | Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2022 | 562 |
34 | Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma | Nature Communications | 2016 | 550 |
35 | Prostate Cancer, Version 1.2016 | Journal of the National Comprehensive Cancer Network: JNCCN | 2016 | 544 |
36 | Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism | Nature Genetics | 2013 | 519 |
37 | Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC | Journal of Thoracic Oncology | 2018 | 515 |
38 | Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer | Cancer Discovery | 2017 | 507 |
39 | Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial | Journal of Clinical Oncology | 2017 | 506 |
40 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2017 | 451 |
41 | Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes | Clinical Cancer Research | 2019 | 447 |
42 | Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer | Journal of Clinical Oncology | 2016 | 444 |
43 | Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma | JAMA Oncology | 2018 | 437 |
44 | Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial | Journal of Clinical Oncology | 2018 | 431 |
45 | A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) | Annals of Oncology | 2018 | 424 |
46 | Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy | Journal of Clinical Oncology | 2019 | 404 |
47 | Classification of current anticancer immunotherapies | Oncotarget | 2014 | 395 |
48 | Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study | Journal of Clinical Oncology | 2015 | 394 |
49 | NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018 | Journal of the National Comprehensive Cancer Network: JNCCN | 2018 | 394 |
50 | Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology | Journal of the National Comprehensive Cancer Network: JNCCN | 2019 | 393 |